東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

The mononuclear phagocyte system as ...

Caron, Whitney P.

FindBook

Google Book

Amazon

博客來

The mononuclear phagocyte system as a phenotypic probe for nanoparticle pharmacokinetics and pharmacodynamics in preclinical and clinical systems.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	The mononuclear phagocyte system as a phenotypic probe for nanoparticle pharmacokinetics and pharmacodynamics in preclinical and clinical systems./
作者:	Caron, Whitney P.
面頁冊數:	176 p.
附註:	Source: Dissertation Abstracts International, Volume: 75-04(E), Section: B.
Contained By:	Dissertation Abstracts International75-04B(E).
標題:	Pharmaceutical sciences. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3606657
ISBN:	9781303638589

The mononuclear phagocyte system as a phenotypic probe for nanoparticle pharmacokinetics and pharmacodynamics in preclinical and clinical systems.
Caron, Whitney P.

The mononuclear phagocyte system as a phenotypic probe for nanoparticle pharmacokinetics and pharmacodynamics in preclinical and clinical systems. - 176 p.

Source: Dissertation Abstracts International, Volume: 75-04(E), Section: B.

Thesis (Ph.D.)--The University of North Carolina at Chapel Hill, 2013.

This item is not available from ProQuest Dissertations & Theses.

Nanoparticles, or carrier-mediated agents are unique drug delivery platforms that provide numerous advantages, such as greater solubility, duration of exposure, and delivery to the site of action over their small molecule counterparts. However, there is substantial variability in systemic clearance and distribution, tumor delivery, and pharmacologic effects of these agents. This work explores some of the factors that affect the pharmacokinetics and pharmacodynamics of nanoparticle agents in preclinical models and patients. The ultimate goal of this work was to determine whether nanoparticle therapy could be individualized in patients based on some of these factors.

ISBN: 9781303638589Subjects--Topical Terms:

3173021
Pharmaceutical sciences.

The mononuclear phagocyte system as a phenotypic probe for nanoparticle pharmacokinetics and pharmacodynamics in preclinical and clinical systems.
LDR:02846nmm a2200301 4500 001 2064097
005 20151109121419.5
008 170521s2013 ||||||||||||||||| ||eng d
020 $a 9781303638589
035 $a (MiAaPQ)AAI3606657
035 $a AAI3606657
040 $a MiAaPQ $c MiAaPQ
100 1 $a Caron, Whitney P. $3 3178656
245 1 4 $a The mononuclear phagocyte system as a phenotypic probe for nanoparticle pharmacokinetics and pharmacodynamics in preclinical and clinical systems.
300 $a 176 p.
500 $a Source: Dissertation Abstracts International, Volume: 75-04(E), Section: B.
500 $a Adviser: William C. Zamboni.
502 $a Thesis (Ph.D.)--The University of North Carolina at Chapel Hill, 2013.
506 $a This item is not available from ProQuest Dissertations & Theses.
520 $a Nanoparticles, or carrier-mediated agents are unique drug delivery platforms that provide numerous advantages, such as greater solubility, duration of exposure, and delivery to the site of action over their small molecule counterparts. However, there is substantial variability in systemic clearance and distribution, tumor delivery, and pharmacologic effects of these agents. This work explores some of the factors that affect the pharmacokinetics and pharmacodynamics of nanoparticle agents in preclinical models and patients. The ultimate goal of this work was to determine whether nanoparticle therapy could be individualized in patients based on some of these factors.
520 $a The primary biologic focus was to measure the function of circulating cells in the blood known to play a role in the clearance of nanoparticles. It was determined that the function of monocytes and dendritic cells, as measured by phagocytosis and the production of reactive oxygen species (ROS) could serve as a phenotypic probe in patients. A phenotypic probe is a test that can be administered to a patient as a potential indicator of a drug's pharmacokinetics and pharmacodynamics, which can then be used to individualize therapy. This work uses patients with recurrent epithelial ovarian cancer receiving the nanoparticle PEGylated liposomal doxorubicin (PLD; Doxil) as part of their standard of care. This work shows an association between cell function and the clearance of PLD for both phagocytosis (R2= 0.43, P= 0.04) and production of ROS (R2= 0.61, P= 0.008). This is an encouraging finding for patients in light of the high variability seen with nanoparticle agent pharmacokinetics and pharmacodynamics. Ideally this work will be applied to other nanoparticles and disease states in the future.
590 $a School code: 0153.
650 4 $a Pharmaceutical sciences. $3 3173021
650 4 $a Pharmacology. $3 634543
690 $a 0572
690 $a 0419
710 2 $a The University of North Carolina at Chapel Hill. $b Pharmaceutical Sciences. $3 1285238
773 0 $t Dissertation Abstracts International $g 75-04B(E).
790 $a 0153
791 $a Ph.D.
792 $a 2013
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3606657